NIHI Big Data in Healthcare Research Case Study

Size: px
Start display at page:

Download "NIHI Big Data in Healthcare Research Case Study"

Transcription

1 NIHI Big Data in Healthcare Research Case Study Professor Rob Doughty Heart Foundation Chair of Heart Health National Institute for Health Innovation and the Dept of Medicine, University of Auckland & Green Lane Cardiovascular Service, Auckland City Hospital

2 Brian D. Ata Research Case Study

3 Brian s Father No CVD risk assessment Told he had hypertension Didn t like the beta blocker he was prescribed Had a heart attack: hospitalised, treated with aspirin, given hand written discharge summary Developed heart failure Died suddenly age 56

4 The Life of Brian Brian D. Ata Big D Formative years in a small town in NZ Moved to Auckland for work in his 20s Dabbled in smoking, binge drinking in Queen Street on Friday night and drinking sugary drinks Contributed to big data with membership of 8 different consumer rewards/loyalty programmes

5 Brian, Age 45 CVD Risk assessment Primary care PREDICT assessment Age, gender, smoking, diabetes, BP, chol/hdl, FH/ethnicity 5 year CVD risk 11% Risk communication by practice nurse (Heart Foundation training), using Heart Forecast tool

6 Patient population Electronic medical record NZ adjusted Framingham HS risk algorithm MoH patient specific outcomes: hospital admissions, deaths, drugs, labs PREDICT: electronic decision support software patient specific CVD risk factor profiles PREDICT Slide courtesy of Prof Rod Jackson, VIEW/PREDICT UoA

7

8 Observed 5 yr CVD events (%) yrs yrs yrs yrs NZ adjusted Framingham score (5-yr risk, %) Slide courtesy of Prof Rod Jackson, VIEW/PREDICT UoA

9 Who to treat with what: NZGG CVD guidelines Select people for risk assessment 5 y CVD risk < 10% CVD general advice only 10-15% Specific lifestyle assessment and advice >15% or prior CVD event Intensive CVD risk managementpatient specific lifestyle advice + drug therapy

10 Daily Mail 2012

11 Daily Mail 2012

12 Brian has a heart attack 2am, 30 minutes away from Auckland Hospital Transferred straight to the catheter lab Angiogram Severe left anterior descending artery stenosis, with thrombus Interventional cardiologist primary stenting

13

14 Relevance of Big Data to Brian Should thrombus in a coronary artery be aspirated prior to stenting? TASTE Trial 7244 heart attack patients in Sweden randomised to stenting or thrombus aspiration then stenting Equivalent mortality at 30 days (3% vs 2.8%) Conclusion: don t aspirate the clot

15 New Era in Trials SCAAR Swedish Coronary Angiography and Angioplasty Register Registry based RCT Online randomisation module Broad inclusion criteria, wide generalisability Rapidly conducted, at low cost

16

17

18 2200km, 13 days, 1.5x Everest ascent 1000 Power Bars 1500 litres of Peak Fuel 2 boxes of Keywin A very large number of bananas.

19 Brian moves to the USA Brian is breathless Primary care in Sutter Health Big data analytics to detect heart failure 3.3million clinical case notes Iterative annotation refinement Detection of clinical criteria for heart failure diagnosis in EMR Byrd et al. Int J Med Inform 2013

20 Brian moves back to NZ Diagnosed with heart failure Normal heart pump function? What is Brian s prognosis?

21 Meta-Analysis Global Group in Chronic Heart Failure. EHJ 2012 Outcome for patients with heart failure with preserved or reduced pump function 31 studies, 50,991 patients Individual patient data collated Outcome: all-cause mortality Length of follow-up: 3 years

22 Meta-Analysis Global Group in Chronic Heart Failure. EHJ 2012 N (31studies) Age Women, % Medical history Hypertension Prior MI AF Diabetes Ischaemic aetiology Whole Group 50, (12) HF-PEF HF-REF Missing LVEF 10, (12) , (12) (13) Deaths 11,987 2,422 8,332 1,233

23 Meta-Analysis Global Group in Chronic Heart Failure. EHJ 2012 Death from any cause Death by LVEF Group HF-PEF HR 0.68 (95% CI 0.64, 0.71) 3 40 Mortality (%) HF-REF HF-PEF Adjusted Hazard Ratio (Mortality) 2 1 er at risk: Years 0 < Ejection Fraction (%)

24 What is Brian s Prognosis? heartfailurerisk.org

25 Big Data Big data concepts integral part of cardiovascular medicine Big data is the wrong terminology Tangible clinical benefits for patients and populations Major potential for improvements in healthcare

Swedish RWE a goldmine?

Swedish RWE a goldmine? Swedish RWE a goldmine? How is Novartis using Swedish RWE to improve decision making? Madlaina Costa, Head Health Economics and Pricing, Novartis Sweden RWE in Europe, Amsterdam 3 rd June 2015 Swedish

More information

EMR Tutorial Acute Coronary Syndrome

EMR Tutorial Acute Coronary Syndrome EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.

More information

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

CARDIAC REHABILITATION

CARDIAC REHABILITATION Paul Peacock Cardiac Rehabilitation Nurse Friday, 4 August 2006 1 The rehab Team Chris Murphy Kate O Reilly Paul Peacock Increased to 2 FTEs March 06 Wellington & Kapiti Coast MDT involvement Friday, 4

More information

Heart Attack: What You Need to Know

Heart Attack: What You Need to Know A WorkLife4You Guide Heart Attack: What You Need to Know What is a Heart Attack? The heart works 24 hours a day, pumping oxygen and nutrient-rich blood to the body. Blood is supplied to the heart through

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,

More information

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith Māori Pathways to and Through Health Care for STEMIs in New Zealand Summer Studentship Research by Ellie Tuzzolino- Smith Terminology & Current Practice STEMI: S-T elevation Myocardial Infarction. Determined

More information

2013 ACO Quality Measures

2013 ACO Quality Measures ACO 1-7 Patient Satisfaction Survey Consumer Assessment of HealthCare Providers Survey (CAHPS) 1. Getting Timely Care, Appointments, Information 2. How well Your Providers Communicate 3. Patient Rating

More information

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data

More information

Diabetes Complications

Diabetes Complications Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example Ulf Stenestrand, MD, PhD Department of Cardiology University Hospital Linköping Chairman RIKS-HIA Register

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

GENERAL HEART DISEASE KNOW THE FACTS

GENERAL HEART DISEASE KNOW THE FACTS GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to

More information

CARDIAC CARE. Giving you every advantage

CARDIAC CARE. Giving you every advantage CARDIAC CARE Giving you every advantage Getting to the heart of the matter The Cardiovascular Program at Northwest Hospital & Medical Center is dedicated to the management of cardiovascular disease. The

More information

Stroke Care First week

Stroke Care First week Stroke Care First week Florence Nightingale (1820 1910) Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available

More information

Success factors in Behavioral Medicine

Success factors in Behavioral Medicine Success factors in Behavioral Medicine interventions post myocardial infarction Depression Gunilla post myocardial Burell, PhD infarction Department of Public Health, Uppsala University, Sweden XIII Svenska

More information

The Bioresorbable Vascular Stent Dr Albert Ko

The Bioresorbable Vascular Stent Dr Albert Ko The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of

More information

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics

More information

How do you decide on rate versus rhythm control?

How do you decide on rate versus rhythm control? How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Randomized trials versus observational studies

Randomized trials versus observational studies Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James

More information

Social inequalities in all cause and cause specific mortality in a country of the African region

Social inequalities in all cause and cause specific mortality in a country of the African region Social inequalities in all cause and cause specific mortality in a country of the African region Silvia STRINGHINI 1, Valentin Rousson 1, Bharathi Viswanathan 2, Jude Gedeon 2, Fred Paccaud 1, Pascal Bovet

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012 Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced

More information

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with

More information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory

More information

Hormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group

Hormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group Hormone therapy and breast cancer: conflicting evidence Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group The world of hormone therapy in the 1990 s Throughout the 1970s, 1980s and 1990s

More information

Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,

More information

Prevention of stroke in patients with atrial fibrillation

Prevention of stroke in patients with atrial fibrillation www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment

More information

From Concept to Rapid Visualization a Data Analytics Case Study

From Concept to Rapid Visualization a Data Analytics Case Study From Concept to Rapid Visualization a Data Analytics Case Study Gregory Wozniak, PhD Director of Outcomes Analytics Health Outcomes Group American Medical Association The Journey Objectives Share experiences

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of

More information

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?

More information

John Radcliffe Hospital, Oxford Heart Centre. Discharge advice after your coronary angiogram, angioplasty or stent insertion (PCI)

John Radcliffe Hospital, Oxford Heart Centre. Discharge advice after your coronary angiogram, angioplasty or stent insertion (PCI) John Radcliffe Hospital, Oxford Heart Centre Discharge advice after your coronary angiogram, angioplasty or stent insertion (PCI) This booklet contains important information. Please read it carefully.

More information

LEADERS: 5-Year Follow-up

LEADERS: 5-Year Follow-up LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS

More information

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,

More information

HealthCare Partners of Nevada. Heart Failure

HealthCare Partners of Nevada. Heart Failure HealthCare Partners of Nevada Heart Failure Disease Management Program 2010 HF DISEASE MANAGEMENT PROGRAM The HealthCare Partners of Nevada (HCPNV) offers a Disease Management program for members with

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.

More information

Using 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions

Using 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions Using 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions Experience with ICES and CNODES DAVID HENRY, PROFESSOR OF HEALTH SYSTEMS DATA, UNIVERSITY OF TORONTO, SENIOR SCIENTIST, INSTITUTE

More information

Renovascular Hypertension

Renovascular Hypertension Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension

More information

Rx Updates New Guidelines, New Medications What You Need to Know

Rx Updates New Guidelines, New Medications What You Need to Know Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact

More information

Discharge Information after a Coronary Angiogram or Coronary Angioplasty/ Stent Procedure

Discharge Information after a Coronary Angiogram or Coronary Angioplasty/ Stent Procedure Discharge Information after a Coronary Angiogram or Coronary Angioplasty/ Stent Procedure FORM # W-00500 June 2014 Discharge Information after a Coronary Angiogram or Coronary Angioplasty/ Stent Procedure

More information

CORONARY ARTERY BYPASS GRAFT & HEART VALVE SURGERY

CORONARY ARTERY BYPASS GRAFT & HEART VALVE SURGERY CORONARY ARTERY BYPASS GRAFT & HEART VALVE SURGERY www.cpmc.org/learning i learning about your health What to Expect During Your Hospital Stay 1 Our Team: Our cardiac surgery specialty team includes nurses,

More information

Cardiovascular Disease Strategic Action Plan

Cardiovascular Disease Strategic Action Plan Cardiovascular Disease Strategic Action Plan Adopted by the Board July 2007 TU1UT TUExecutive TU2UT TUIntroductionUT...2 TU3UT TUPatterns TU4UT TUService TU5UT TUGoals TU6UT TUImplementing TUAge-standardised

More information

Telemedicine in the Prevention and Monitoring of Heart Disease

Telemedicine in the Prevention and Monitoring of Heart Disease Telemedicine in the Prevention and Monitoring of Heart Disease Prof. Dr. med. Friedrich Köhler 26. April 2012 Charité-Universitätsmedizin Berlin Facts Founded in 1710 11 Nobel laureates 12.922 employees

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

ECONOMIC COSTS OF PHYSICAL INACTIVITY

ECONOMIC COSTS OF PHYSICAL INACTIVITY ECONOMIC COSTS OF PHYSICAL INACTIVITY This fact sheet highlights the prevalence and health-consequences of physical inactivity and summarises some of the key facts and figures on the economic costs of

More information

Alexandra Bargiota Assist. Prof. in Endocrinology University Hopsital of Larissa Thessaly, Greece. www.united4health.eu

Alexandra Bargiota Assist. Prof. in Endocrinology University Hopsital of Larissa Thessaly, Greece. www.united4health.eu Applying Evidence-Based Medicine with Telehealth the clinician view Assessing the impact of telehealth/telemedicine either via an RCT or an observational study the voice of a clinician Alexandra Bargiota

More information

Type 1 Diabetes ( Juvenile Diabetes)

Type 1 Diabetes ( Juvenile Diabetes) Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.

More information

Quantifying Life expectancy in people with Type 2 diabetes

Quantifying Life expectancy in people with Type 2 diabetes School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by

More information

Know your Numbers The D5 Goals for Diabetes Care. Shelly Hanson RN, CNS, CDE Cuyuna Regional Medical Center November 6, 2014

Know your Numbers The D5 Goals for Diabetes Care. Shelly Hanson RN, CNS, CDE Cuyuna Regional Medical Center November 6, 2014 Know your Numbers The D5 Goals for Diabetes Care Shelly Hanson RN, CNS, CDE Cuyuna Regional Medical Center November 6, 2014 The D5 What is it 5 different treatment goals identified for optimal diabetes

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

Introduction to study design

Introduction to study design Introduction to study design Doug Altman EQUATOR Network, Centre for Statistics in Medicine, NDORMS, University of Oxford EQUATOR OUCAGS training course 4 October 2014 Objectives of the day To understand

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

Outcome of in-patient Treatment for Severe Motor Conversion Disorder - does it work? A.S.David, R.McCormack and Lishman Unit MDT

Outcome of in-patient Treatment for Severe Motor Conversion Disorder - does it work? A.S.David, R.McCormack and Lishman Unit MDT Outcome of in-patient Treatment for Severe Motor Conversion Disorder - does it work? A.S.David, R.McCormack and Lishman Unit MDT Evidence to date: inpatient rehab Inpatient multi-disciplinary intervention

More information

Kardiovaskuläre Erkrankungen ein Update für die Praxis, 22. Mai 2014 PD Dr. Matthias Wilhelm

Kardiovaskuläre Erkrankungen ein Update für die Praxis, 22. Mai 2014 PD Dr. Matthias Wilhelm Bewegungsbasierte kardiale Rehabilitation als 3. Säule fit für die Zukunft? Matthias Wilhelm Cardiovascular Prevention, Rehabilitation & Sports Medicine University Clinic for Cardiology Interdisciplinary

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

DECLARATION OF CONFLICT OF INTEREST. None

DECLARATION OF CONFLICT OF INTEREST. None DECLARATION OF CONFLICT OF INTEREST None Predicting Survival in Chronic Heart Failure: A Risk Score based on 39372 Patients from 30 Studies Stuart Pocock London School of Hygiene and Tropical Medicine

More information

Promoting CVD Prevention in Your Practice: A New Medicare Reimbursable Service

Promoting CVD Prevention in Your Practice: A New Medicare Reimbursable Service Promoting CVD Prevention in Your Practice: A New Medicare Reimbursable Service Richard Josephson, MD, MS, Professor of Medicine, Case Western Reserve University; Medical Director, CICU, UH Case Medical

More information

Absolute cardiovascular disease risk assessment

Absolute cardiovascular disease risk assessment Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk

More information

Table 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure

Table 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure Table 1 Performance Measures # Category Performance Measure 1 Behavioral Health Risk Assessment and Follow-up 1) Behavioral Screening/ Assessment within 60 days of enrollment New Enrollees who completed

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

California Health and Safety Code, Section 1256.01

California Health and Safety Code, Section 1256.01 California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program

More information

High Blood Pressure (Essential Hypertension)

High Blood Pressure (Essential Hypertension) Sacramento Heart & Vascular Medical Associates February 18, 2012 500 University Ave. Sacramento, CA 95825 Page 1 916-830-2000 Fax: 916-830-2001 What is essential hypertension? Blood pressure is the force

More information

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014 Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

Heart information. Cardiac rehabilitation

Heart information. Cardiac rehabilitation Heart information Cardiac rehabilitation Contents 2 What is cardiac rehabilitation? 3 What are the benefits of cardiac rehabilitation? 4 Who should take part in cardiac rehabilitation? 4 When does cardiac

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

3.5% 3.0% 3.0% 2.4% Prevalence 2.0% 1.5% 1.0% 0.5% 0.0%

3.5% 3.0% 3.0% 2.4% Prevalence 2.0% 1.5% 1.0% 0.5% 0.0% S What is Heart Failure? 1,2,3 Heart failure, sometimes called congestive heart failure, develops over many years and results when the heart muscle struggles to supply the required oxygen-rich blood to

More information

Big Data for Population Health and Personalised Medicine through EMR Linkages

Big Data for Population Health and Personalised Medicine through EMR Linkages Big Data for Population Health and Personalised Medicine through EMR Linkages Zheng-Ming CHEN Professor of Epidemiology Nuffield Dept. of Population Health, University of Oxford Big Data for Health Policy

More information

Heart Failure: From Prevention to Intervention

Heart Failure: From Prevention to Intervention Sharp HealthCare Presents Heart Failure: From Prevention to Intervention Saturday, May 16, 2015 DoubleTree by Hilton Hotel San Diego - Mission Valley San Diego, Calif. As medical professionals, we know

More information

RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75

RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75 ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin

More information

Atrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller

Atrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Your Results. For more information visit: www.sutton.gov.uk/healthchecks. Name: Date: In partnership with

Your Results. For more information visit: www.sutton.gov.uk/healthchecks. Name: Date: In partnership with Your Results Name: Date: For more information visit: www.sutton.gov.uk/healthchecks In partnership with Introduction Everyone is at risk of developing diabetes, heart disease, kidney disease, stroke and

More information

With Big Data Comes Big Responsibility

With Big Data Comes Big Responsibility With Big Data Comes Big Responsibility Using health care data to emulate randomized trials when randomized trials are not available Miguel A. Hernán Departments of Epidemiology and Biostatistics Harvard

More information

PHARMACEUTICAL BIGDATA ANALYTICS

PHARMACEUTICAL BIGDATA ANALYTICS PHARMACEUTICAL BIGDATA ANALYTICS ANDINSIGHTS December 2013 Strategic Research Insights, Inc. 2013 Sources of Big Data in rpharmaceutical and Healthcare Industry Challenges with Big Data in Pharma Oncology

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Scottish Clinical Coding

Scottish Clinical Coding Scottish Clinical Coding Standards Number 3 September 2013 Scottish Clinical Coding Standards - ICD10 Factor V Leiden Factor V Leiden is the name of a specific gene mutation that results in thrombophilia

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary

More information

Tackling the Semantic Interoperability challenge

Tackling the Semantic Interoperability challenge European Patient Summaries: What is next? Tackling the Semantic Interoperability challenge Dipak Kalra Cross-border health care The context for sharing health summaries Also useful for within-border health

More information

Swedish Initiative for Research on Microdata in the Social And Medical Sciences

Swedish Initiative for Research on Microdata in the Social And Medical Sciences Swedish Initiative for Research on Microdata in the Social And Medical Sciences www.simsam.nu GOCARTS Kardiovaskulär epidemiologi hjärtinfarkt och stroke www.registerforskning.se GOCARTs (Gothenburg CArdiovascular

More information

PG Certificate / PG Diploma / MSc in Clinical Pharmacy

PG Certificate / PG Diploma / MSc in Clinical Pharmacy PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme

More information

Most probable Diagnosis

Most probable Diagnosis Most probable Diagnosis Evidence from monitoring Blood Pressure Measured using home monitoring device weekly 165 Peak reading 150 Average reading 130 Min reading Evidence from EMR Family history of Essential

More information

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease Erich Minar Medical University Vienna for the Task Force on the Diagnosis and Treatment of Peripheral

More information

Cardiac Rehabilitation

Cardiac Rehabilitation Cardiac Rehabilitation Introduction Experiencing heart disease should be the beginning of a new, healthier lifestyle. Cardiac rehabilitation helps you in two ways. First, it helps your heart recover through

More information